`Attorney Docket No.: AKBM-14409/US-9/CON
`
`REMARKS
`
`Claims 1-20 are pending and under examination following entry of the Responseto the
`
`Final Office Action filed on April 16, 2015.
`
`Applicant respectfully requests that the Examiner additionally consider the disclosure of
`
`Tanakaet al., Biosci. Biotech. Biochem. 59(8):1389-93 (1995) which demonstrates that the
`
`deleterious PAF-like analogs described in Maranteet al. (1999) 274(10):28395-28404 are readily
`
`formed from ether phospholipids found in krill. In fact, as described in the Tanakaabstract:
`
`
`The activity of oxidized krill PC, which was equivalent of 89.8 + 8.8 pmol 16:0
`
`PAF/umolofstarting PC, was about five times those of oxidized PCs from salmon roe
`
`and sea urchin eggs and about 50 times that of oxidized hen yolk PC.
`
`Based on this information, and the knownplatelet aggregation and inflammatory activity of PAF,
`
`one of skill in the art would not be motivated to increase the ether phospholipid content of prior
`
`art krill oil and would in fact have been motivated to avoid increasing the ether phospholipid
`
`content of krill oil. Certainly, one of skill in the art would not have expected that increasing the
`
`ether phospholipid contentof krill oil would lead to increased health benefits.
`
`CONCLUSION
`
`If a telephone interview wouldaid in the prosecution of this application, the Examineris
`
`encouragedto call the undersigned collect at (608) 662-1277.
`
`Dated:
`
`April 23, 2015
`
`/J. Mitchell Jones/
`John Mitchell Jones
`Registration No. 44,174
`Casimir Jones, S.C.
`2275 Deming Way,Suite 310
`Middleton, WI, 53562
`(608) 662-1277
`
`